Compare AbbVie Inc (ABBV) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Qurate Retail Inc Series A — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Qurate Retail Inc Series A trades at $0.09 (market cap $1.12M). The key difference: AbbVie Inc is far larger — about 401705.4× Qurate Retail Inc Series A's market cap, and AbbVie Inc pays a 2.72% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| ABBV | QVCAQ | |
|---|---|---|
Market Cap | $449.91B | $1.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $15.03 |
52-Week Low | $184.85 | $0.07 |
Enterprise Value | $513.38B | $4.74B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
QVCAQ trades at $0.109, up 37.97% in 24 hours, but technical signals are bearish with 13 sell signals on moving averages. The company reported a net loss of $2.44 billion in 2025, with negative shareholder equity of $971 million and a debt-to-asset ratio of 77.57%. Recent news highlights QVC's 40th anniversary and TikTok Shop partnership (PRNewsWire, 2026-05-28).
The outlook remains highly speculative due to persistent losses, negative equity, and high leverage. Risks include financial distress and competitive pressures, while any positive sentiment hinges on operational turnarounds. Investors should approach with caution given the fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
